Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Renovaro Biosciences ( (RENB) ) has provided an update.
On July 7, 2025, Renovaro Inc. restructured its debt by entering into an Exchange Agreement with existing accredited investors, converting $9.7 million in secured promissory notes into $16.1 million in new convertible promissory notes. These notes were immediately converted into 53.6 million shares of common stock, eliminating the secured debt and providing the company with greater financial flexibility. This transaction, which did not require stockholder approval under Nasdaq rules, is expected to support Renovaro’s strategic initiatives without involving any cash proceeds.
More about Renovaro Biosciences
Average Trading Volume: 3,560,936
Technical Sentiment Signal: Sell
Current Market Cap: $51.03M
For detailed information about RENB stock, go to TipRanks’ Stock Analysis page.